

Alberta Diabetes Institute - Johnson & Johnson Diabetes Research Fund 2015

Overview

In partnership with Johnson & Johnson, the Alberta Diabetes Foundation and the Government of Alberta, the Alberta Diabetes Institute (ADI) is pleased to invite applications from Alberta-based investigators or teams of investigators for the ADI - Johnson & Johnson Diabetes Research Fund. The research fund is in year two of a three-year commitment created in 2014.

The fund is aimed at supporting research in either Type I or Type II diabetes *with a focus on novel, discovery research and a high potential for commercialization*. The application process will include a Letter of Intent (see below) evaluated by a review committee that includes industry representation. This will be followed by invitation for full application. Up to a maximum of \$50,000 for one (1) year may be requested.

Scope of award and important dates

Research ideas should be highly innovative and hypothesis-driven, the outcome of which have the potential to alter the course of existing treatment or diagnosis for Type I or II diabetes patients. Research may be at either the *in vitro* or early *in vivo* level, and encouraging results are expected to lead to further development of the technology towards commercializable drugs, devices, cell therapies, kits, etc.

Important dates

LOI due date: April 2, 2015

Notification date of successful LOI submission: May 29, 2015

Full application due date: June 30, 2015

Notification letters to successful applicants: July 31, 2015

Eligibility and conditions

- Full-time faculty appointees of any Alberta-based post-secondary institution can act as principal or co-applicant.
- Researchers can be a principal applicant for one application and co-investigator on one additional application. If they are not a principal applicant, they may be co-investigator on a maximum of two applications.

Letter of Intent guidelines

Applicants must submit a Letter of Intent (LOI) that will be competitively evaluated by a review committee based on scientific merit and relevance to the goals of the ADI/J&J fund. The LOI must not exceed **two (2) pages** excluding references, tables and figures. The LOI should be written with typeface no smaller than 12 pt font and should include the following information:

1. Name of applicant and co-applicant(s) (if any)
2. Applicant(s) institution(s)
3. Project title
4. Background
5. Proposed research and its novelty
6. How the research addresses an important and unmet need for diabetes patients
7. Methodology overview
8. Budget outline

Note: Not more than 50% of requested funds can be used for salaries of technical personnel or trainees working directly on the project. Additionally, not more than \$5,000 can be used for equipment expenditures. Administrative overhead costs, which are incidental expenses like protocol approvals, special training, packaging/shipping, set up costs, etc. that are directly related to the project are also allowable expenses.

The deadline for submission of the LOI is noon on April 2, 2015.

Please submit this by email (preferably in PDF format) to Rosemarie Henley, ADI rhenley@ualberta.ca

Full proposal

For those successful in proceeding to the full application stage, invitations will be sent out May 29, 2015. Instructions for submitting full proposals will be given at that time.

Non-confidentiality, non-disclosure and intellectual property (IP) protection

Letters of intent will be accepted solely on a non-confidential basis, and should not contain any Applicant or third party confidential information. Information pertaining to letters of intent and subsequent full proposals will not be disclosed beyond the review committee. The Terms of Reference for the ADI/J&J award stipulate that any data generated using these funds will be evaluated by the review committee for commercial potential prior to any dissemination (publications, conferences, media etc.). This ensures that IP will be appropriately protected prior to results being disclosed.

Additional funding support

The first year of funding carries with it the possibility of renewal for a larger amount and/or partnership with Johnson & Johnson for product development, depending on progress, translational potential and satisfactory reporting.

If you have any questions related to the LOI for the ADI/J&J Diabetes Research Fund, please contact:

Rosemarie Henley

ALBERTA DIABETES INSTITUTE

University of Alberta

1-002 Li Ka Shing Centre for Health Research Innovation

Edmonton, AB T6G 2E1

rhenley@ualberta.ca

780-492-3386

The deadline for submission of the LOI is noon on April 2, 2015

Please submit this by email (preferably in PDF format) to Rosemarie Henley, ADI (see email above)